JP2009532373A5 - - Google Patents

Download PDF

Info

Publication number
JP2009532373A5
JP2009532373A5 JP2009503137A JP2009503137A JP2009532373A5 JP 2009532373 A5 JP2009532373 A5 JP 2009532373A5 JP 2009503137 A JP2009503137 A JP 2009503137A JP 2009503137 A JP2009503137 A JP 2009503137A JP 2009532373 A5 JP2009532373 A5 JP 2009532373A5
Authority
JP
Japan
Prior art keywords
composition
jnk
intraocular
formulation
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009503137A
Other languages
English (en)
Japanese (ja)
Other versions
JP5241033B2 (ja
JP2009532373A (ja
Filing date
Publication date
Priority claimed from US11/394,893 external-priority patent/US7803824B2/en
Application filed filed Critical
Publication of JP2009532373A publication Critical patent/JP2009532373A/ja
Publication of JP2009532373A5 publication Critical patent/JP2009532373A5/ja
Application granted granted Critical
Publication of JP5241033B2 publication Critical patent/JP5241033B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009503137A 2006-03-31 2007-03-14 緑内障を処置するためのjunn末端キナーゼの阻害剤の使用 Expired - Fee Related JP5241033B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/394,893 US7803824B2 (en) 2004-10-29 2006-03-31 Use of inhibitors of Jun N-terminal kinases to treat glaucoma
US11/394,893 2006-03-31
PCT/US2007/063961 WO2007117849A2 (en) 2006-03-31 2007-03-14 Use of inhibitors of jun n-terminal kinases to treat glaucoma

Publications (3)

Publication Number Publication Date
JP2009532373A JP2009532373A (ja) 2009-09-10
JP2009532373A5 true JP2009532373A5 (https=) 2011-03-10
JP5241033B2 JP5241033B2 (ja) 2013-07-17

Family

ID=38523463

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009503137A Expired - Fee Related JP5241033B2 (ja) 2006-03-31 2007-03-14 緑内障を処置するためのjunn末端キナーゼの阻害剤の使用

Country Status (13)

Country Link
US (3) US7803824B2 (https=)
EP (1) EP2004158A2 (https=)
JP (1) JP5241033B2 (https=)
KR (1) KR20080108503A (https=)
CN (1) CN101415407B (https=)
AR (1) AR060222A1 (https=)
AU (1) AU2007235111B2 (https=)
BR (1) BRPI0710099A2 (https=)
CA (1) CA2644721A1 (https=)
MX (1) MX2008011319A (https=)
TW (1) TWI419694B (https=)
WO (1) WO2007117849A2 (https=)
ZA (1) ZA200807667B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7803824B2 (en) * 2004-10-29 2010-09-28 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases to treat glaucoma
US20060094753A1 (en) * 2004-10-29 2006-05-04 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases
US20090202524A1 (en) * 2007-10-31 2009-08-13 Alcon Research, Ltd. Pai-1 expression and activity inhibitors for the treatment of ocular disorders
US20100056609A1 (en) * 2008-08-26 2010-03-04 Washington University Methods and compositions for inhibition of axonal degeneration by modulation of the dlk/jnk pathway
WO2010151638A1 (en) * 2009-06-25 2010-12-29 Medical College Of Georgia Research Institute, Inc. Jnk inhibitors for use in treating spinal muscular atrophy
JP2014511391A (ja) * 2011-03-07 2014-05-15 フォンダッツィオーネ・テレソン Tfebリン酸化阻害剤およびその使用
ES2870085T3 (es) * 2013-06-26 2021-10-26 Xigen Inflammation Ltd Inhibidores peptídicos permeables a células de la ruta de transducción de señales de JNK para el tratamiento de la cistitis
WO2015197194A2 (en) * 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997040847A1 (en) * 1996-04-26 1997-11-06 University Of Ottawa Therapeutic and drug screening methods for the treatment and prevention of neuronal disease
CA2347519A1 (en) 1998-10-13 2000-04-20 Kyowa Hakko Kogyo Co., Ltd. An agent for treating ophthalmopathy
PT1149092E (pt) 1998-12-17 2004-03-31 Hoffmann La Roche 4- e 5-alciniloxindois e 4- e 5-alceniloxindois
EP1175399B1 (en) 1999-04-23 2009-03-11 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk)
MXPA02001565A (es) 1999-08-13 2005-07-14 Vertex Pharma Inhibidores de cinasas c-jun n-terminal (jnk) y de otras cinasas proteicas.
US20040072888A1 (en) 1999-08-19 2004-04-15 Bennett Brydon L. Methods for treating inflammatory conditions or inhibiting JNK
HK1053107A1 (zh) 1999-08-19 2003-10-10 Signal Pharmaceuticals, Inc. 作为jnk抗化剂的pyrazoloanthrone及其衍生物和它们的成份
EP1088821A1 (en) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonamide derivatives
EP1088815A1 (en) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonyl amino acid derivatives
EP1088822A1 (en) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonyl hydrazide derivatives
EP1110957A1 (en) 1999-12-24 2001-06-27 Applied Research Systems ARS Holding N.V. Benzazole derivatives and their use as JNK modulators
CA2410475A1 (en) 2000-06-01 2001-12-06 Merck & Co., Inc. Use of (di-substituted-phenyl)-pyrimidinyl-imidazole derivatives as jnk-inhibitors
EP1193256A1 (en) 2000-09-27 2002-04-03 Applied Research Systems ARS Holding N.V. Pharmaceutically active benzsulfonamide derivatives as inhibitors of JNK proteins
US7129242B2 (en) 2000-12-06 2006-10-31 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
CA2437248A1 (en) 2001-02-02 2002-08-15 Takeda Chemical Industries, Ltd. Jnk inhibitor
GB0108770D0 (en) 2001-04-06 2001-05-30 Eisai London Res Lab Ltd Inhibitors
CN1300116C (zh) 2001-04-16 2007-02-14 卫材株式会社 1h-吲唑化合物
CA2458131A1 (en) 2001-08-23 2003-03-06 Takeda Chemical Industries, Ltd. Jnk activation inhibitor
IL160915A0 (en) 2001-09-19 2004-08-31 Aventis Pharma Sa Indolizines inhibiting kinase proteins
JP2003129190A (ja) 2001-10-19 2003-05-08 Sumitomo Metal Ind Ltd マルテンサイト系ステンレス鋼およびその製造方法
US20030138819A1 (en) 2001-10-26 2003-07-24 Haiqing Gong Method for detecting disease
DE60332215D1 (de) * 2002-02-28 2010-06-02 Eisai R&D Man Co Ltd Neue indazolverbindungen mit kondensiertem ring
WO2003092584A2 (en) * 2002-04-30 2003-11-13 Alcon, Inc. Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies
EP1527070B1 (en) 2002-06-14 2013-01-09 Merck Serono SA Azole methylidene cyanide derivatives and their use as protein kinase modulators
CA2497977A1 (en) 2002-09-20 2004-04-01 Alcon, Inc. Use of cytokine synthesis inhibitors for the treatment of dry eye disorders
US20040092568A1 (en) 2002-10-31 2004-05-13 Zeldis Jerome B. Methods for the treatment, prevention and management of macular degeneration
US7803824B2 (en) * 2004-10-29 2010-09-28 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases to treat glaucoma
US20060094753A1 (en) 2004-10-29 2006-05-04 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases
US20060275797A1 (en) * 2005-03-21 2006-12-07 Alcon Manufacturing, Ltd. Use of agents which inhibit connective tissue growth factor (CTGF) binding and signaling via the TrkA/p75NTR receptor complex for the prevention and treatment of CTGF-mediated ocular disorders

Similar Documents

Publication Publication Date Title
JP2009532373A5 (https=)
RU2017139870A (ru) Новые агонисты npr-b
NZ588938A (en) Sustained release delivery of active agents to treat glaucoma and ocular hypertension
IL176416A (en) History of Nitroxy prostaglandin, pharmaceutical preparations containing them, and their use in the preparation of the drug for the treatment of glaucoma or intraocular pressure
JP6014033B2 (ja) 防腐剤無添加ビマトプロストおよびチモロール溶液
JP2008540532A5 (https=)
JP2015025011A5 (https=)
JP2018529693A5 (https=)
JP2021518352A5 (https=)
EP2052720A3 (en) Use of at least one hydroxylamine compound for the treatment of eye disease
JP5616620B2 (ja) 非イオン性シリコーンハイドロゲルコンタクトレンズ用眼科組成物
JP2014515383A5 (https=)
RU2431502C2 (ru) Фармацевтические композиции для лечения сухости глаз
WO2010075315A2 (en) Topical formulations of flap inhibitors for administration to an eye
JP5616617B2 (ja) シリコーンハイドロゲルコンタクトレンズ用点眼剤
JP2008540533A5 (https=)
JP2008540528A5 (https=)
RU2009122167A (ru) Композиция для нанесения на кожу или слизистую оболочку
JPWO2019166631A5 (https=)
JP2019534296A5 (https=)
JP5725786B2 (ja) 非イオン性シリコーンハイドロゲルコンタクトレンズ用眼科組成物
JP2020169211A (ja) シリコーンハイドロゲルコンタクトレンズ用点眼剤
CN105530936B (zh) 两性离子性软隐形眼镜用眼科用组合物
JPWO2019206956A5 (https=)
CN101969950A (zh) 用于治疗或控制前段炎症的包含游离的糖皮质激素受体激动剂的组合物